Intellia Therapeutics Inc Stock News

While it's a common conspiracy theory – and comedic punchline – that medical innovators only seek to manage problems rather than cure them, the reality is that several biotech stocks to buy underg

Cathie Wood (Catherine Duddy Wood) is the founder and CEO of ARK Invest. Before founding ARK Invest, Wood was with AllianceBernstein as Chief Investment Officer of Global Thematic Strategies.

CRISPR could revolutionize the way we treat thousands of diseases. Currently, there are about 7,000 caused by genetic disorders, which occur when a mutation affects your genes, or when you have the wr

Intellia Therapeutics' (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, gets Regenerative Medicine Advanced Therapy designation for the treatment of hereditary angioedema.

With multiple promising candidates in its pipeline, Intellia is well-positioned to capitalize on the growing demand for gene editing therapies. The recent clearance of its IND application by the FDA f

Investing in Cathie Wood stocks means directing your money toward innovation. And that means investing heavily in tech, a sector that has been pummeled by interest rates held higher by a Federal Reser

Amid yet another soft session on Wall Street, biotechnology firm Intellia Therapeutics (NASDAQ: NTLA ) brightened the room considerably. Receiving a regulatory green light from the Food and Drug Admin

Intellia Therapeutics landed a historic regulatory nod from the FDA.

The FDA cleared Intellia to begin testing its CRISPR gene-editing technology in people on Thursday, leading NTLA stock to jump. The post Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Ge

Shares of Intellia Therapeutics Inc. NTLA, +1.44% rallied about 10% in premarket trading on Thursday after the company said the Food and Drug Administration will allow its experimental CRISPR therapy

Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q4 2022 Results Conference Call February 23, 2023 8:00 AM ET Company Participants Ian Karp - Senior Vice President, Investor Relations and Corporate Communic

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 0% and 11.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the st

Here is how Intellia Therapeutics, Inc. (NTLA) and Centogene N.V. (CNTG) have performed compared to their sector so far this year.

Over the next 10 to 20 years, some of healthcare's most impactful innovations will come from biotechnology companies. They'll produce medicines based on living organisms that will save and improve the

The two clinical-stage gene-editing companies have good long-term prospects.